FDA Achieves Historically Low Eight-Month Median Drug Review Time In 2017
Executive Summary
Median review times for US agency's drug center were 10 months from 2011 to 2013, and 11 months from 2015 to 2016.
You may also be interested in...
FDA Reviewers Share CMC, GMP Challenges In Last Year's Rush To Approve New Therapies
Inundated with high-priority applications last year, US FDA's CMC reviewers struggled with seemingly thrown-together review packages, moving-target manufacturing processes and not-on-the-same-page contract manufacturers.
FDA Bests Annual Novel Drug Approval Record With Four Oks In One Week
The agency's Dec. 21 approval of Giapreza became novel drug No. 46 of 2017, topping the 2015 mark of 45.
Keeping Track: US FDA Approves Siliq, Accepts Mylan/Biocon Pegfilgrastim Biosimilar
The latest drug development news and highlights from our FDA Performance Tracker.